Biotech Values

[DewDiligence]

IDIX – The main MoA benefit of IDX184 relative to “first generation” HCV nukes—bypassing the in vivo first phosphorylation step—may not be clear from the slide you posted. Bypassing the first phosphorylation step is highly consequential because in vivo performance of this step is inefficient. Thus, a nuke that already has the first phosphate group attached, as IDX184 does, can be dosed at a much level than a nuke that doesn’t, which improves safety and tolerability for a given degree of efficacy.